-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

Benzinga·09/24/2026 18:02:01
语音播报
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.